 Kala Pharmaceuticals Eysuvis, a corticosteroid-based drug, was approved for both signs and symptoms of dry eye disease last year and sale calls began on Jan 4th 2021. The market uptake of Eysuvis has been good so far and will likely speed up further after more insurers come on board. 